Abstract: Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreatic tumors.

Abstract: Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreatic tumors.

Abstract: A process for determining whether or not a cancer cell-containing test sample originating from or containing human cells has potential for tumor development, tumor progression or metastasis, wherein the test sample and a second sample originating from non-tumor cells obtained from the same individual or a different individual of the same species are analyzed by incubating each respective sample with a nucleic probe of sequence SEQ ID NO:1 and determining the approximate amount of hybridization of each respective sample with said probe, and comparing the approximate amount of hybridization of the test sample to an approximate amount of hybridization of said second sample to identify whether or not the test sample contains a greater amount of the specific nucleic acid or mixture of nucleic acids than does said second sample.

Abstract: Polynucleotide and polypeptide SMAGP are specific for tumors. Diagnosis of SMAGP is therefore valuable for diagnosis of tumors. Antibodies against SMAGP are, besides their value in diagnosis, useful as therapeutic agents in the treatment of tumors.

Abstract: A pharmaceutical composition is disclosed, as well as its use in tumour diagnosis, therapy and prevention, methods for diagnosing, treating and preventing tumours, and antibodies and their use.

Abstract: Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreatic tumors.

Abstract: A nucleic acid molecule (PKW) with the nucleic acid sequence SEQ ID NO:1 is upregulated in mammary carcinoma cells. The PKW protein of SEQ ID NO:2 and SEQ ID NO:4 is also provided. A process for determining whether a sample contains tumor cells is provided.

Abstract: The present invention concerns a mammalian cell line which when co-cultured with lymphocytes during which allogenic stimulation is avoided activates lymphocytes fo form tumoricidal cells, a process for the production of tumoricidal T lymphocytes by co-culturing lymphocytes with this cell line, the tumoricidal T lymphocytes obtained by means of this process and the use of the cells according to the present invention for the production of a therapeutic agent which can be used in tumour therapy.

Abstract: The invention concerns an antibody composition which inhibits the binding of interleukin 2 to its high affinity receptor and contains (1) monoclonal antibodies against the &agr; chain of the interleukin 2 receptor and (2) monoclonal antibodies against the &bgr; chain of the interleukin 2 receptor, as well as a pharmaceutical agent which contains the antibody composition according to the present invention.

Abstract: The present invention provides peptides as inhibitors of the binding of urokinase to the urokinase receptor. The peptides have the general structural formula (I): X1-[X2]n-X3-X4-K-Y-F-X5-X6-I-X7-W-[X8]m  (I) in which X1, X2, X3, X4, X5, X6, X7 and X8 each denote an aminocarboxylic acid, n and m are each independently 0 or 1, K denotes an aminocarboxylic acid with a lysine side chain, Y denotes an aminocarboxylic acid with a tyrosine side chain, F denotes an aminocarboxylic acid with a phenyl-alanine side chain, I denotes an aminocarboxylic acid with an isoleucine side chain, W denotes an aminocarboxylic acid with a tryptophan side chain, and the monomeric building blocks are linked by —CONR1— or —NR1CO— bonds where R1 in each case independently denotes hydrogen, methyl or ethyl, and pharmaceutically compatible salts and derivatives thereof.

Abstract: A pharmaceutical composition is disclosed, as well as its use in tumour diagnosis, therapy and prevention, methods for diagnosing, treating and preventing tumours, and antibodies and their use.

Abstract: The present invention concerns a mammalian cell line which when co-cultured with lymphocytes during which allogenic stimulation is avoided activates lymphocytes fo form tumoricidal cells, a process for the production of tumoricidal T lymphocytes by co-culturing lymphocytes with this cell line, the tumoricidal T lymphocytes obtained by means of this process and the use of the cells according to the present invention for the production of a therapeutic agent which can be used in tumour therapy.

Abstract: A nucleic acid molecule (URIM) with the nucleic acid sequence SEQ ID NO:1 is capable of inducing tumor progression and/or metastasis. The URIM protein of SEQ ID NO:2 is also provided. A process for determining whether a tumor sample has metastatic potential is provided.

Abstract: For the production of hetero-bispecific monoclonal antibodies at least the genes for the light chain and for the variable part of the heavy chain are isolated from a hybridoma cell line which secretes an antibody with a desired specificity and they are inserted into a eukaryotic plasmid vector which contains a marker capable of selection together with a strong promoter, this expression vector is transfected into a hybridoma cell line which secretes antibodies with a second desired specificity, the cell line is cultured, the antibodies are obtained and the bispecific antibody is isolated.

Abstract: The invention relates to an antibody which inhibits the binding between u-PA and u-PAR to an extent of at least 90% in an assay as defined in the specification, or an active fragment or immunological equivalent of said antibody. Examples of such antibodies are deposited Jul. 7, 1994 at Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSM) with accession numbers DSM ACC2178 and DSM ACC2179 under the terms and conditions of the Budapest Treaty. The invention furthermore relates to a method for detecting or quantifying u-PAR or a glycosylation variant of u-PAR in a sample by use of an antibody according to the invention.Furthermore, the invention relates to a method for the manufacture of a therapeutic agent for preventing or counteracting localized proteolytic activity using of an antibody of the invention as well as to use of an antibody according to the invention for the preparation of a diagnostic agent which is capable of targeting a diagnostic to a cell that contains a u-PAR on the surface.

Abstract: Process for the production of proteins with antibody activity in which one or several DNA sequences coding for this protein are introduced into the male pronucleus of a fertilized ovum of a pig or rabbit by microinjection, the ova are implanted in the oviduct of a pig or rabbit, the offspring are bred and the protein with antibody activity is isolated from their serum in the usual way whereby the DNA sequences used for the microinjection are free of bacterial foreign sequences, and are preferably used with immunoglobulin promoter and enhancer sequences.

Abstract: The invention concerns a recombinant DNA which codes for a protein with the domains G, K1 and L of t-PA in which the sequences coding for the domains K2 and F of the wild-type t-PA gene or the sequences derived therefrom within the scope of the degeneration of the genetic code are completely deleted according to the exact exon/intron borders on the t-PA gene. The invention also relates to a process for the production of a recombinant DNA according to the present invention. In addition the invention concerns vectors containing this recombinant DNA as well as cells which are transformed with vectors according to the present invention or with the DNA according to the present invention.

Abstract: The present invention provides a vector for the expression of heterologous proteins in mammalian cells, wherein it contains at least one first consensus sequence is homologous to the ##STR1## in at least 10 nucleotides in total and including the first three thereof and at least one second sequence which in one of the 6th, 8th, 9th and 10th nucleotide, as well as in at least 9 nucleotides, is homologous to the sequence ##STR2## or in at least 10 nucleotides is homologous to the sequenceTATGATAATGAGor is homologous to the sequenceTGG(N).sub.6-7 GCCAA.